Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Lake Bioscience Co's Accounts Payable for the quarter that ended in Mar. 2026 was ¥1,696 Mil.
Star Lake Bioscience Co's quarterly Accounts Payable
increased
from Sep. 2025 (¥1,039 Mil) to Dec. 2025 (¥1,474 Mil) and
increased
from Dec. 2025 (¥1,474 Mil) to Mar. 2026 (¥1,696 Mil).
Star Lake Bioscience Co's annual Accounts Payable
increased
from Dec. 2023 (¥1,040 Mil) to Dec. 2024 (¥1,257 Mil) and
increased
from Dec. 2024 (¥1,257 Mil) to Dec. 2025 (¥1,474 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Lake Bioscience Co Accounts Payable Calculation
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Star Lake Bioscience Co (SHSE:600866) has a Accounts Payable of ¥1,696 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Star Lake Bioscience Co and its competitors.
Is Star Lake Bioscience Co's Accounts Payable too high?
Star Lake Bioscience Co's current Accounts Payable is ¥1,696 Mil. Overall, Star Lake Bioscience Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Star Lake Bioscience Co's Accounts Payable compare to VRTX and REGN?
Star Lake Bioscience Co's Accounts Payable of ¥1,696 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Star Lake Bioscience Co and its competitors. Star Lake Bioscience Co's current Accounts Payable is ¥1,696 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Lake Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Star Lake Bioscience Co (SHSE:600866) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.88, compared to a current price of ¥4.52 — trading 23.1% below its estimated fair value. The current Accounts Payable is ¥1,696 Mil. Star Lake Bioscience Co's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Star Lake Bioscience Co (SHSE:600866), the current Accounts Payable is ¥1,696 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Lake Bioscience Co (SHSE:600866) Overvalued in 2026?
Based on GuruFocus' analysis, Star Lake Bioscience Co stock appears to be undervalued.
The current stock price of ¥4.52 is trading 23.1% below its estimated GF Value™ of ¥5.88.
GuruFocus considers Star Lake Bioscience Co to be Modestly Undervalued.
Key valuation signals for SHSE:600866:
Accounts Payable: ¥1,696 Mil
GF Value™: ¥5.88 vs. price of ¥4.52 (23.1% below fair value)
No single metric tells the full story. See the SHSE:600866 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
71GF Score
Get the complete analysis for SHSE:600866
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600866 has been successfully added to your 
